DE60320652D1 - Zusammensetzung frei von ascorbicsäure enthaltend einen hemmer der cholesterinabsorption, einen hemmer der hmg-coa reduktase und ein stabilisierungsmittel - Google Patents
Zusammensetzung frei von ascorbicsäure enthaltend einen hemmer der cholesterinabsorption, einen hemmer der hmg-coa reduktase und ein stabilisierungsmittelInfo
- Publication number
- DE60320652D1 DE60320652D1 DE60320652T DE60320652T DE60320652D1 DE 60320652 D1 DE60320652 D1 DE 60320652D1 DE 60320652 T DE60320652 T DE 60320652T DE 60320652 T DE60320652 T DE 60320652T DE 60320652 D1 DE60320652 D1 DE 60320652D1
- Authority
- DE
- Germany
- Prior art keywords
- inhibitor
- cholesterine
- hmg
- stabilizer
- absorption
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 title 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 title 1
- 229960005070 ascorbic acid Drugs 0.000 title 1
- 235000010323 ascorbic acid Nutrition 0.000 title 1
- 239000011668 ascorbic acid Substances 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 1
- 239000003381 stabilizer Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39869102P | 2002-07-26 | 2002-07-26 | |
US398691P | 2002-07-26 | ||
PCT/US2003/022889 WO2004010993A1 (en) | 2002-07-26 | 2003-07-22 | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60320652D1 true DE60320652D1 (de) | 2008-06-12 |
DE60320652T2 DE60320652T2 (de) | 2009-06-10 |
Family
ID=31188454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60320652T Revoked DE60320652T2 (de) | 2002-07-26 | 2003-07-22 | Zusammensetzung frei von ascorbicsäure enthaltend einen hemmer der cholesterinabsorption, einen hemmer der hmg-coa reduktase und ein stabilisierungsmittel |
Country Status (39)
Country | Link |
---|---|
US (4) | US7229982B2 (de) |
EP (2) | EP1992343A1 (de) |
JP (2) | JP2005538104A (de) |
KR (2) | KR20080070089A (de) |
CN (2) | CN101069684A (de) |
AR (2) | AR040588A1 (de) |
AT (1) | ATE393628T1 (de) |
AU (2) | AU2003261217B2 (de) |
BR (1) | BR0312933A (de) |
CA (1) | CA2493076A1 (de) |
CR (1) | CR9767A (de) |
DE (1) | DE60320652T2 (de) |
DK (1) | DK1531805T3 (de) |
EA (1) | EA008888B1 (de) |
EC (2) | ECSP055573A (de) |
ES (1) | ES2303603T3 (de) |
GE (1) | GEP20084443B (de) |
GT (2) | GT200300149A (de) |
HK (1) | HK1080384A1 (de) |
HR (2) | HRP20050081A2 (de) |
IL (2) | IL166279A0 (de) |
IS (1) | IS7637A (de) |
MA (1) | MA27289A1 (de) |
ME (3) | ME00207B (de) |
MX (1) | MXPA05001004A (de) |
MY (1) | MY148689A (de) |
NO (2) | NO20051033L (de) |
NZ (1) | NZ537611A (de) |
PA (1) | PA8577901A1 (de) |
PE (1) | PE20050128A1 (de) |
PL (1) | PL375065A1 (de) |
PT (1) | PT1531805E (de) |
RS (2) | RS50419B (de) |
SI (1) | SI1531805T1 (de) |
TN (1) | TNSN05022A1 (de) |
TW (2) | TW200412944A (de) |
UA (1) | UA82489C2 (de) |
WO (1) | WO2004010993A1 (de) |
ZA (1) | ZA200500196B (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
AR040588A1 (es) * | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
US7320972B2 (en) * | 2003-11-10 | 2008-01-22 | Microbia, Inc. | 4-Biarylyl-1-phenylazetidin-2-ones |
ATE485267T1 (de) | 2003-12-23 | 2010-11-15 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
KR100598326B1 (ko) | 2004-04-10 | 2006-07-10 | 한미약품 주식회사 | HMG-CoA 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법 |
US20060046996A1 (en) * | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
EP1741427A1 (de) | 2005-07-06 | 2007-01-10 | KRKA, D.D., Novo Mesto | Pharmazeutische Zusammensetzung enthaltend Simvastatin und Ezetimibe |
EP1905424A3 (de) * | 2006-02-02 | 2008-04-30 | Ranbaxy Laboratories Limited | Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, die stabilisierte Statin-Partikel enthält |
EP1849459A1 (de) * | 2006-03-06 | 2007-10-31 | Teva Pharmaceutical Industries Ltd. | Ezetimibzusammensetzungen |
TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
EP2526932B1 (de) | 2006-06-19 | 2017-06-07 | Alpharma Pharmaceuticals LLC | Pharmazeutische Zusammensetzung |
CN1994296B (zh) * | 2006-08-02 | 2010-06-16 | 浙江京新药业股份有限公司 | 一种含有辛伐他汀的药物制剂 |
GB0713707D0 (en) | 2007-07-13 | 2007-08-22 | Generics Uk Ltd | Stable compositions |
AU2008281640A1 (en) * | 2007-07-27 | 2009-02-05 | Cipla Limited | Pharmaceutical compositions and process for making them |
WO2009024889A2 (en) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
AU2008337435A1 (en) * | 2007-12-17 | 2009-06-25 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Suspension comprising non-micronized ezetimibe micro-particles |
US20090233898A1 (en) * | 2008-03-11 | 2009-09-17 | Glenmark Generics Ltd | Pharmaceutical Compositions Comprising Simvastatin and Ezetimibe |
TR200806302A2 (tr) * | 2008-08-22 | 2010-03-22 | Bi̇lgi̇ç Mahmut | Çözünürlük ve stabilite artırıcı farmasötik formülasyon. |
EP2168573A1 (de) | 2008-09-30 | 2010-03-31 | LEK Pharmaceuticals D.D. | Zubereitungen enthaltend Ezetimib |
MX344885B (es) * | 2008-11-10 | 2017-01-10 | Psicofarma S A De C V | Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido. |
EP2204170A1 (de) * | 2008-12-01 | 2010-07-07 | LEK Pharmaceuticals D.D. | Pharmazeutische Zusammensetzung mit Ezetimibe und Simvastatin |
WO2010066687A2 (en) * | 2008-12-11 | 2010-06-17 | Dsm Ip Assets B.V. | Stabalized statin-comprising compositions |
EP2216016A1 (de) | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, die Ezetimib umfasst |
WO2011002424A2 (en) * | 2009-07-02 | 2011-01-06 | Bilgic Mahmut | Solubility and stability enchancing pharmaceutical formulation |
EP2448919A2 (de) * | 2009-07-02 | 2012-05-09 | Mahmut Bilgic | Löslichkeits- und stabilitätsverstärkende pharmazeutische formulierung |
WO2011002422A2 (en) * | 2009-07-02 | 2011-01-06 | Bilgic Mahmut | Solubility enhancing pharmaceutical formulation |
EP2368543A1 (de) | 2010-03-25 | 2011-09-28 | KRKA, tovarna zdravil, d.d., Novo mesto | Verfahren zur Herstellung einer granulierten pharmazeutischen Zusammensetzung mit Simvastatin und/oder Ezetimibe |
KR101302243B1 (ko) * | 2010-07-28 | 2013-09-02 | 씨제이제일제당 (주) | 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물 |
CN101978953A (zh) * | 2010-10-11 | 2011-02-23 | 上海交通大学 | 基于易吸湿性辅料的固体制剂 |
EP2468258A1 (de) | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, die einen wenig löslichen, pharmazeutisch wirksamen Bestandteil umfasst |
US20140141090A1 (en) | 2011-02-02 | 2014-05-22 | Edward S. Wilson | Pharmaceutical Composition Comprising Opioid Agonist And Sequestered Antagonist |
CN102266323B (zh) * | 2011-08-04 | 2013-03-27 | 海南锦瑞制药股份有限公司 | 依折麦布和辛伐他汀组合物及其制备方法 |
EP2753309B1 (de) * | 2011-09-08 | 2020-01-01 | Hexal AG | Pharmazeutische zusammensetzung zur oralen darreichung mit einem statin |
WO2013166114A1 (en) * | 2012-05-01 | 2013-11-07 | Althera Life Sciences, Llc | Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe |
MX365046B (es) * | 2012-05-01 | 2019-05-17 | Althera Life Sciencies Llc | Formulacion de tableta oral que consiste de una combinacion fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares. |
RU2547574C2 (ru) * | 2013-07-09 | 2015-04-10 | Общество с ограниченной ответственностью "Трейдсервис" | Лекарственная форма гиполипидемического действия и способ ее изготовления |
CN103585146B (zh) * | 2013-11-09 | 2015-04-01 | 北京中申专利科技有限公司 | 辛伐他汀的药物组合物 |
TWI586380B (zh) * | 2013-12-18 | 2017-06-11 | 夢製藥公司 | 包含HMG-CoA還原酶抑制劑及膽固醇吸收抑制劑之醫藥組合製劑 |
CN104306348B (zh) * | 2014-09-30 | 2017-05-31 | 地奥集团成都药业股份有限公司 | 一种辛伐他汀片及其制备方法 |
CN108366957A (zh) * | 2015-11-06 | 2018-08-03 | 燿石治疗公司 | 用于治疗心血管疾病的吉卡宾组合 |
CN106937952A (zh) * | 2016-01-04 | 2017-07-11 | 重庆华邦制药有限公司 | 依折麦布和辛伐他汀的制剂 |
EP3281649A1 (de) * | 2016-08-09 | 2018-02-14 | Teleflex Lifesciences | Netzmittelformulierung |
JP6937195B2 (ja) * | 2017-09-01 | 2021-09-22 | 興和株式会社 | 医薬組成物 |
CN111601590A (zh) * | 2017-11-23 | 2020-08-28 | 浙江海正药业股份有限公司 | 一种海泽麦布片剂及其制备方法 |
US11833133B2 (en) * | 2020-08-13 | 2023-12-05 | Orient Pharma Co., Ltd. | Solid oral pharmaceutical composition |
TWI760067B (zh) * | 2020-08-13 | 2022-04-01 | 友霖生技醫藥股份有限公司 | 固態口服醫藥組成物 |
CN112168801A (zh) * | 2020-10-22 | 2021-01-05 | 哈药集团技术中心 | 一种辛伐他汀片的制备方法 |
CN115227659B (zh) * | 2022-08-19 | 2023-05-02 | 北京百奥药业有限责任公司 | 一种依折麦布辛伐他汀组合物及其制备方法 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US5366738A (en) * | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
AU1422388A (en) | 1987-01-27 | 1988-08-10 | Warner-Lambert Company | Lipid regulating compositions |
US4820850A (en) | 1987-07-10 | 1989-04-11 | Merck & Co., Inc. | Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof |
US4916239A (en) | 1988-07-19 | 1990-04-10 | Merck & Co., Inc. | Process for the lactonization of mevinic acids and analogs thereof |
US4990535A (en) | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
CA2040865C (en) | 1990-05-15 | 2002-07-23 | James L. Bergey | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor |
US5622985A (en) | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
IL100091A (en) | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole) |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5688785A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US5688787A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
DE69222532T2 (de) | 1991-07-23 | 1998-02-26 | Schering Corp | Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung |
US5162117A (en) | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
CA2085871C (en) * | 1991-12-27 | 2002-05-07 | Gerald S. Rork | A controlled release drug dispersion delivery device |
LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
JPH06247854A (ja) * | 1993-02-24 | 1994-09-06 | Ss Pharmaceut Co Ltd | アスコルビン酸含有組成物 |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5976570A (en) | 1993-12-21 | 1999-11-02 | Applied Analytical Industries, Inc. | Method for preparing low dose pharmaceutical products |
US6369103B1 (en) | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
US5627176A (en) | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
WO1995035277A1 (en) * | 1994-06-20 | 1995-12-28 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US6268392B1 (en) * | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
AU2453295A (en) | 1994-09-20 | 1996-04-19 | Pfizer Inc. | Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor |
US5633246A (en) | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5624920A (en) | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5656624A (en) | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
AR004701A1 (es) * | 1995-10-31 | 1999-03-10 | Schering Corp | 2-azetidinonas substituidas con azucares utiles como agentes hipocolesterolemicos, composicion farmaceutica, proceso para la preparacion dedicha composicion, uso de dichos compuestos para fabricar medicamentos y un equipo. |
EP0904082A4 (de) * | 1996-04-17 | 2001-09-26 | Merck & Co Inc | Kombinationstherapie zur verminderung der mit herz-kreislauferkrankungen einhergenden risiken |
US6673831B1 (en) | 1996-04-17 | 2004-01-06 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
AU4326197A (en) | 1996-07-09 | 1998-02-02 | Merck & Co., Inc. | Pharmaceutical compositions |
FR2751540B1 (fr) | 1996-07-26 | 1998-10-16 | Sanofi Sa | Composition pharmaceutique antithrombotique |
US5952003A (en) | 1996-08-01 | 1999-09-14 | Novartis Corporation | Terazosin capsules |
US6251852B1 (en) | 1996-09-18 | 2001-06-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
US6235706B1 (en) | 1996-09-18 | 2001-05-22 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
US5756470A (en) | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
US6245797B1 (en) * | 1997-10-22 | 2001-06-12 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease |
FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
AU4699099A (en) | 1998-06-24 | 2000-01-10 | Merck & Co., Inc. | Compositions and methods for treating elevated blood cholesterol |
WO1999066929A1 (en) | 1998-06-24 | 1999-12-29 | Merck & Co., Inc. | Compositions and methods for treating elevated blood cholesterol |
US6099865A (en) | 1998-07-08 | 2000-08-08 | Fmc Corporation | Croscarmellose taste masking |
US6268352B1 (en) * | 1998-09-02 | 2001-07-31 | The Regents Of The University Of California | Promoters of neural regeneration |
JP2000109882A (ja) * | 1998-10-01 | 2000-04-18 | Nof Corp | 油性粉末、製造方法および用途 |
SA99191255B1 (ar) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
US6207822B1 (en) | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
EP1163203A1 (de) | 1999-03-08 | 2001-12-19 | Merck & Co., Inc. | Wasserhaltiges, kristallines calcium-salz der simvastatin dihydroxy offene säure |
JP2002538202A (ja) | 1999-03-08 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | HMG−CoAレダクターゼ阻害剤のジヒドロキシオープンアシッド及びその塩 |
EP1158977B1 (de) | 1999-03-10 | 2005-10-12 | G.D. Searle LLC | Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere |
JP2000302672A (ja) * | 1999-04-16 | 2000-10-31 | Taisho Pharmaceut Co Ltd | 咀嚼可能な被覆錠剤 |
JP3732039B2 (ja) * | 1999-05-21 | 2006-01-05 | 三菱化学フーズ株式会社 | 錠剤用組成物 |
DZ3179A1 (fr) | 1999-08-03 | 2001-02-08 | Lilly Icos Llc | Compositions pharmaceutiques à base de beta-carboline. |
US6328995B1 (en) * | 1999-09-24 | 2001-12-11 | Basf Aktiengesellschaft | Stable vitamin and/or carotenoid products in powder form and process for their production |
AU1756201A (en) | 1999-12-08 | 2001-06-18 | Pharmacia Corporation | Nanoparticulate eplerenone compositions |
AU2276801A (en) | 1999-12-20 | 2001-07-03 | Schering Corporation | Extended release oral dosage composition |
US6248359B1 (en) | 2000-01-05 | 2001-06-19 | Laboratorios Phoenix U.S.A., Inc. | Multi-tablet oxybutynin system for treating incontinence |
DK1267880T4 (da) | 2000-02-29 | 2010-05-17 | Bristol Myers Squibb Co | Entecavir-formulering med lav dosis og anvendelse deraf |
WO2002020457A1 (en) * | 2000-09-06 | 2002-03-14 | Merck & Co., Inc. | Dihydroxy open-acid salt of simvastatin |
US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
SK286703B6 (sk) * | 2000-12-20 | 2009-03-05 | Schering Corporation | Cukrom-substituované 2-azetidinóny, farmaceutický prostriedok s ich obsahom a ich použitie |
CA2432145C (en) * | 2000-12-28 | 2010-07-13 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
IL156422A0 (en) | 2001-01-26 | 2004-01-04 | Schering Corp | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
BR0206644A (pt) | 2001-01-26 | 2004-02-25 | Schering Corp | Combinações de inibidor(es) de absorção de esteróis com agente(s) cardiovascular(es) para o tratamento de condições vasculares |
JP2004517920A (ja) | 2001-01-26 | 2004-06-17 | シェーリング コーポレイション | 血管状態を治療するためのステロール吸収阻害剤と血液調整剤との組合せ |
AU2002241956A1 (en) | 2001-01-26 | 2002-08-06 | Schering Corporation | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
PT1413331E (pt) | 2001-01-26 | 2007-12-18 | Schering Corp | Combinações do activador do receptor activado por proliferador do peroxisoma (ppar) fenofibrato e inibidor da absorção de esterol para indicações vasculares. |
DE60206365T2 (de) | 2001-03-28 | 2006-07-06 | Schering Corporation, Kenilworth | Verfahren für die enantioselektive synthese von azetidinon-zwischenprodukten |
AR040588A1 (es) * | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
-
2003
- 2003-07-16 AR AR20030102560A patent/AR040588A1/es unknown
- 2003-07-17 MY MYPI20032695A patent/MY148689A/en unknown
- 2003-07-21 PE PE2003000726A patent/PE20050128A1/es not_active Application Discontinuation
- 2003-07-22 EA EA200500279A patent/EA008888B1/ru not_active IP Right Cessation
- 2003-07-22 SI SI200331222T patent/SI1531805T1/sl unknown
- 2003-07-22 US US10/625,004 patent/US7229982B2/en not_active Expired - Fee Related
- 2003-07-22 MX MXPA05001004A patent/MXPA05001004A/es active IP Right Grant
- 2003-07-22 IL IL16627903A patent/IL166279A0/xx unknown
- 2003-07-22 ME MEP-2008-308A patent/ME00207B/me unknown
- 2003-07-22 UA UAA200501756A patent/UA82489C2/uk unknown
- 2003-07-22 NZ NZ537611A patent/NZ537611A/en not_active IP Right Cessation
- 2003-07-22 KR KR1020087017824A patent/KR20080070089A/ko not_active Application Discontinuation
- 2003-07-22 ES ES03771709T patent/ES2303603T3/es not_active Expired - Lifetime
- 2003-07-22 RS YUP-2005/0061A patent/RS50419B/sr unknown
- 2003-07-22 CN CNA2007100850256A patent/CN101069684A/zh active Pending
- 2003-07-22 DK DK03771709T patent/DK1531805T3/da active
- 2003-07-22 PA PA20038577901A patent/PA8577901A1/es unknown
- 2003-07-22 BR BR0312933-0A patent/BR0312933A/pt not_active IP Right Cessation
- 2003-07-22 CA CA002493076A patent/CA2493076A1/en not_active Abandoned
- 2003-07-22 WO PCT/US2003/022889 patent/WO2004010993A1/en active Application Filing
- 2003-07-22 EP EP08103776A patent/EP1992343A1/de not_active Withdrawn
- 2003-07-22 GT GT200300149A patent/GT200300149A/es unknown
- 2003-07-22 GT GT200300149AK patent/GT200300149AA/es unknown
- 2003-07-22 KR KR1020057001458A patent/KR20050045993A/ko not_active Application Discontinuation
- 2003-07-22 DE DE60320652T patent/DE60320652T2/de not_active Revoked
- 2003-07-22 JP JP2004524692A patent/JP2005538104A/ja active Pending
- 2003-07-22 EP EP03771709A patent/EP1531805B1/de not_active Revoked
- 2003-07-22 ME MEP-308/08A patent/MEP30808A/xx unknown
- 2003-07-22 ME MEP-2008-47A patent/ME00008B/me unknown
- 2003-07-22 PL PL03375065A patent/PL375065A1/xx not_active Application Discontinuation
- 2003-07-22 RS RSP-2008/0072A patent/RS20080072A/sr unknown
- 2003-07-22 GE GEAP8662A patent/GEP20084443B/en unknown
- 2003-07-22 CN CNB038178443A patent/CN1310643C/zh not_active Expired - Fee Related
- 2003-07-22 PT PT03771709T patent/PT1531805E/pt unknown
- 2003-07-22 AT AT03771709T patent/ATE393628T1/de not_active IP Right Cessation
- 2003-07-22 AU AU2003261217A patent/AU2003261217B2/en not_active Ceased
- 2003-07-25 TW TW092120442A patent/TW200412944A/zh unknown
- 2003-07-25 TW TW097131985A patent/TW200906388A/zh unknown
-
2005
- 2005-01-10 ZA ZA200500196A patent/ZA200500196B/en unknown
- 2005-01-10 IS IS7637A patent/IS7637A/is unknown
- 2005-01-25 HR HR20050081A patent/HRP20050081A2/xx not_active Application Discontinuation
- 2005-01-25 EC EC2005005573A patent/ECSP055573A/es unknown
- 2005-01-26 TN TNP2005000022A patent/TNSN05022A1/en unknown
- 2005-02-11 MA MA28095A patent/MA27289A1/fr unknown
- 2005-02-25 NO NO20051033A patent/NO20051033L/no unknown
-
2006
- 2006-01-12 HK HK06100504A patent/HK1080384A1/xx not_active IP Right Cessation
-
2007
- 2007-03-12 US US11/716,595 patent/US20070160666A1/en not_active Abandoned
-
2008
- 2008-02-26 CR CR9767A patent/CR9767A/es unknown
- 2008-02-28 EC EC20080055732008005573A patent/ECSP085573A/es unknown
- 2008-03-12 US US12/047,223 patent/US20080275020A1/en not_active Abandoned
- 2008-05-08 NO NO20082156A patent/NO20082156L/no not_active Application Discontinuation
- 2008-05-11 IL IL191348A patent/IL191348A0/en unknown
- 2008-06-09 JP JP2008150227A patent/JP2008291034A/ja not_active Withdrawn
- 2008-06-17 AR ARP080102576A patent/AR067030A2/es not_active Application Discontinuation
- 2008-10-16 HR HR20080518A patent/HRP20080518A2/xx not_active Application Discontinuation
-
2009
- 2009-02-26 AU AU2009200768A patent/AU2009200768A1/en not_active Abandoned
- 2009-05-26 US US12/472,021 patent/US7718643B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60320652D1 (de) | Zusammensetzung frei von ascorbicsäure enthaltend einen hemmer der cholesterinabsorption, einen hemmer der hmg-coa reduktase und ein stabilisierungsmittel | |
ATE345683T1 (de) | Malonsäuerenitril-verbindungen und ihre verwendung als pestizide | |
DE60316440D1 (de) | Benzo-kondensierte heteroarylamid-derivative von thienopyridinen nützlich als therapeutische agentien, entsprechende pharmazeutische zusammensetzungen, und methoden für ihre verwendung | |
DE60123210D1 (de) | Picolinsäure-derivate und ihre verwendung als fungizide | |
DE502005009089D1 (de) | 1-methyl-3-trifluormethyl-pyrazol-4-carbonsäure-(ortho-phenyl)-anilide und ihre verwendung als fungizid | |
DE60208661D1 (de) | Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren | |
NO20043642L (no) | Heterocykiske tripeptider som hepatitt C inhibitorer | |
ATE339419T1 (de) | Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren | |
ATE443048T1 (de) | 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren | |
DE60312659D1 (de) | Leichtgewicht identifizierung von informationen | |
DE602005013923D1 (de) | Derivate von piperidinylalkylcarbamaten, herstellungsverfahren davon und verwendung derselben als faah-enzym-inhibitoren | |
ATE510556T1 (de) | Verwendung von erythropoietin | |
DE602005015486D1 (de) | Esterderivate von ascorbinsäure und 2-ketosäuresacchariden | |
DE60321808D1 (de) | Flavon derivate als inhibitoren von cyclin-abhängigen kinasen | |
ATE417842T1 (de) | Verwendung von trisubstituierten benzopyranonen | |
DE60321958D1 (de) | Indazolderivate und ihre verwendung als crf antagonisten | |
DE50212455D1 (de) | Verwendung von Dimerdiolen | |
DE502004011575D1 (de) | Verwendung von Dioldimerfettsäureestern | |
DE502005009430D1 (de) | Verwendung von tensiden bei der metallgewinnung | |
DE60309344D1 (de) | Derivate von ä6, 7-dihydro -5h-imidazoä1,2 - aüimidazol -3 -sulfonylaminoü-propionamid und deren verwendung als inhibitoren der interaktion von cams und leukointreginen | |
EA200301101A1 (ru) | Производные пиперазина и их применение в качестве ингибиторов pde4 | |
ATE369371T1 (de) | 1-azadibenzoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung | |
ATE413396T1 (de) | Pyrazindicarbonsäureamide und ihre verwendung | |
WO2006027345A3 (en) | Novel 3-thia-10-aza-phenanthrene derivatives | |
WO2005075457A8 (en) | Phthalazinone-derivatives as pde4 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8331 | Complete revocation |